Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels

Heidi J. Wehring, Teresa Elsobky, Joseph Patrick McEvoy, Gopal Vyas, Charles M. Richardson, Robert P. McMahon, Bethany A. DiPaula, Fang Liu, Kelli Sullivan, Robert W. Buchanan, Stephanie Feldman, Elizabeth M. McMahon, Deanna L. Kelly

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

Clozapine is the sole antipsychotic agent effective for the treatment of refractory schizophrenia. Sixty percent of clozapine-treated patients, however, fail to adequately respond. Minocycline, a tetracycline antibiotic, possesses antiinflammatory and neuroprotective properties that may play a role in schizophrenia. Clozapine is mainly metabolized by CYP1A2 enzymes, and minocycline may potentially inhibit CYP1A2 as hypothesized by case report data. To date, no pharmacokinetic interaction has been reported between minocycline and clozapine. This is a secondary analysis of a 10-week controlled study of adjunctive minocycline to clozapine in treatment refractory schizophrenia. Clozapine plasma levels were collected every two weeks during the study. 28 participants assigned to receive minocycline and 22 assigned to placebo were included. No differences existed in baseline demographics, clozapine dose or plasma levels. Average changes from baseline in clozapine plasma level (p = 0.033) were significantly higher in the minocycline group despite maintenance of stable doses. No statistically significant treatment differences were found in the norclozapine (p = 0.754) or total clozapine (p = 0.053) changes in plasma levels, although possible changes in total clozapine levels require further investigation. This analysis suggests that minocycline administration may lead to increased clozapine plasma levels. Further study is needed to examine possible explanations.

LanguageEnglish (US)
Pages73-80
Number of pages8
JournalPsychiatric Quarterly
Volume89
Issue number1
DOIs
StatePublished - Mar 1 2018

Fingerprint

Minocycline
Clozapine
Schizophrenia
Cytochrome P-450 CYP1A2
norclozapine
Tetracycline
Antipsychotic Agents
Anti-Inflammatory Agents
Therapeutics
Pharmacokinetics
Placebos
Maintenance
Demography
Anti-Bacterial Agents

Keywords

  • Clozapine
  • Drug interaction
  • Minocycline
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia : Analyzing the Effects of Minocycline on Clozapine Plasma Levels. / Wehring, Heidi J.; Elsobky, Teresa; McEvoy, Joseph Patrick; Vyas, Gopal; Richardson, Charles M.; McMahon, Robert P.; DiPaula, Bethany A.; Liu, Fang; Sullivan, Kelli; Buchanan, Robert W.; Feldman, Stephanie; McMahon, Elizabeth M.; Kelly, Deanna L.

In: Psychiatric Quarterly, Vol. 89, No. 1, 01.03.2018, p. 73-80.

Research output: Contribution to journalArticle

Wehring, HJ, Elsobky, T, McEvoy, JP, Vyas, G, Richardson, CM, McMahon, RP, DiPaula, BA, Liu, F, Sullivan, K, Buchanan, RW, Feldman, S, McMahon, EM & Kelly, DL 2018, 'Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels' Psychiatric Quarterly, vol. 89, no. 1, pp. 73-80. https://doi.org/10.1007/s11126-017-9515-x
Wehring, Heidi J. ; Elsobky, Teresa ; McEvoy, Joseph Patrick ; Vyas, Gopal ; Richardson, Charles M. ; McMahon, Robert P. ; DiPaula, Bethany A. ; Liu, Fang ; Sullivan, Kelli ; Buchanan, Robert W. ; Feldman, Stephanie ; McMahon, Elizabeth M. ; Kelly, Deanna L. / Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia : Analyzing the Effects of Minocycline on Clozapine Plasma Levels. In: Psychiatric Quarterly. 2018 ; Vol. 89, No. 1. pp. 73-80.
@article{7e7370bcdf2a4668948160394391545f,
title = "Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels",
abstract = "Clozapine is the sole antipsychotic agent effective for the treatment of refractory schizophrenia. Sixty percent of clozapine-treated patients, however, fail to adequately respond. Minocycline, a tetracycline antibiotic, possesses antiinflammatory and neuroprotective properties that may play a role in schizophrenia. Clozapine is mainly metabolized by CYP1A2 enzymes, and minocycline may potentially inhibit CYP1A2 as hypothesized by case report data. To date, no pharmacokinetic interaction has been reported between minocycline and clozapine. This is a secondary analysis of a 10-week controlled study of adjunctive minocycline to clozapine in treatment refractory schizophrenia. Clozapine plasma levels were collected every two weeks during the study. 28 participants assigned to receive minocycline and 22 assigned to placebo were included. No differences existed in baseline demographics, clozapine dose or plasma levels. Average changes from baseline in clozapine plasma level (p = 0.033) were significantly higher in the minocycline group despite maintenance of stable doses. No statistically significant treatment differences were found in the norclozapine (p = 0.754) or total clozapine (p = 0.053) changes in plasma levels, although possible changes in total clozapine levels require further investigation. This analysis suggests that minocycline administration may lead to increased clozapine plasma levels. Further study is needed to examine possible explanations.",
keywords = "Clozapine, Drug interaction, Minocycline, Schizophrenia",
author = "Wehring, {Heidi J.} and Teresa Elsobky and McEvoy, {Joseph Patrick} and Gopal Vyas and Richardson, {Charles M.} and McMahon, {Robert P.} and DiPaula, {Bethany A.} and Fang Liu and Kelli Sullivan and Buchanan, {Robert W.} and Stephanie Feldman and McMahon, {Elizabeth M.} and Kelly, {Deanna L.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s11126-017-9515-x",
language = "English (US)",
volume = "89",
pages = "73--80",
journal = "Psychiatric Quarterly",
issn = "0033-2720",
publisher = "Kluwer Academic/Human Sciences Press Inc.",
number = "1",

}

TY - JOUR

T1 - Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia

T2 - Psychiatric Quarterly

AU - Wehring, Heidi J.

AU - Elsobky, Teresa

AU - McEvoy, Joseph Patrick

AU - Vyas, Gopal

AU - Richardson, Charles M.

AU - McMahon, Robert P.

AU - DiPaula, Bethany A.

AU - Liu, Fang

AU - Sullivan, Kelli

AU - Buchanan, Robert W.

AU - Feldman, Stephanie

AU - McMahon, Elizabeth M.

AU - Kelly, Deanna L.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Clozapine is the sole antipsychotic agent effective for the treatment of refractory schizophrenia. Sixty percent of clozapine-treated patients, however, fail to adequately respond. Minocycline, a tetracycline antibiotic, possesses antiinflammatory and neuroprotective properties that may play a role in schizophrenia. Clozapine is mainly metabolized by CYP1A2 enzymes, and minocycline may potentially inhibit CYP1A2 as hypothesized by case report data. To date, no pharmacokinetic interaction has been reported between minocycline and clozapine. This is a secondary analysis of a 10-week controlled study of adjunctive minocycline to clozapine in treatment refractory schizophrenia. Clozapine plasma levels were collected every two weeks during the study. 28 participants assigned to receive minocycline and 22 assigned to placebo were included. No differences existed in baseline demographics, clozapine dose or plasma levels. Average changes from baseline in clozapine plasma level (p = 0.033) were significantly higher in the minocycline group despite maintenance of stable doses. No statistically significant treatment differences were found in the norclozapine (p = 0.754) or total clozapine (p = 0.053) changes in plasma levels, although possible changes in total clozapine levels require further investigation. This analysis suggests that minocycline administration may lead to increased clozapine plasma levels. Further study is needed to examine possible explanations.

AB - Clozapine is the sole antipsychotic agent effective for the treatment of refractory schizophrenia. Sixty percent of clozapine-treated patients, however, fail to adequately respond. Minocycline, a tetracycline antibiotic, possesses antiinflammatory and neuroprotective properties that may play a role in schizophrenia. Clozapine is mainly metabolized by CYP1A2 enzymes, and minocycline may potentially inhibit CYP1A2 as hypothesized by case report data. To date, no pharmacokinetic interaction has been reported between minocycline and clozapine. This is a secondary analysis of a 10-week controlled study of adjunctive minocycline to clozapine in treatment refractory schizophrenia. Clozapine plasma levels were collected every two weeks during the study. 28 participants assigned to receive minocycline and 22 assigned to placebo were included. No differences existed in baseline demographics, clozapine dose or plasma levels. Average changes from baseline in clozapine plasma level (p = 0.033) were significantly higher in the minocycline group despite maintenance of stable doses. No statistically significant treatment differences were found in the norclozapine (p = 0.754) or total clozapine (p = 0.053) changes in plasma levels, although possible changes in total clozapine levels require further investigation. This analysis suggests that minocycline administration may lead to increased clozapine plasma levels. Further study is needed to examine possible explanations.

KW - Clozapine

KW - Drug interaction

KW - Minocycline

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85018447457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018447457&partnerID=8YFLogxK

U2 - 10.1007/s11126-017-9515-x

DO - 10.1007/s11126-017-9515-x

M3 - Article

VL - 89

SP - 73

EP - 80

JO - Psychiatric Quarterly

JF - Psychiatric Quarterly

SN - 0033-2720

IS - 1

ER -